Drug diversion bill
In a Nov. 3 letter to Sen. Matsunaga (D-Hawaii), sponsor of the Senate drug diversion legislation (S 368), Finance Committee Chairman Bensten (D-Texas) indicates that a full committee markup will be scheduled before the end of the year. Rep. Dingell (D-Mich.), the House sponsor, has urged Bentsen to expedite the legislative process ("The Pink Sheet" Oct. 12, T&G-2).
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”